COMPANY PROFILE · UPDATED 18 NOV 2025

Dermaliq Therapeutics

Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The proprietary technology now owned by Dermaliq, called…

dermaliq.com ↗

This profile is unclaimed — do you work here? Claim it

Claim it →

Founded: 2022
Headcount: 12
Open roles: 0
Last raised: Series A · Sign in to view

LEADERSHIP

Founders & key people

Betsy Hughes-Formella

Chief Officer at Dermaliq Therapeutics

BioskinIndependent ContractorDermatology Clinic, University Medical School, Hamburg, GermanyDepartment of Clinical Chemistry, University Medical School, Hamburg, GermanyDermaliq TherapeuticsUniversity of Georgia, Athens, GA

Oliver Schlüter

CFO at Dermaliq Therapeutics

Novaliqdievini Hopp Biotech HoldingCureVacApogenixDZ BankDZ BANK AG and DZ Equity Partner GmbHBrunel UniversityFrankfurt School of Finance & ManagementEmory UniversityGoizueta Business School

Frank Löscher

CTO at Novaliq

NovaliqCorden Pharma - A Full-Service CDMOinstrActionMMI - Molecular Machines & IndustriesDermaliq TherapeuticsCordenPharmaHeidelberg University

OPEN ROLES

Roles at Dermaliq Therapeutics

Employbl doesn’t track Dermaliq Therapeutics’s job board yet, so there’s nothing to show here — they may still be hiring. You can also search all jobs →

FUNDING